drugset / Trial / NCT07199257

A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.

NCT07199257 ↗

Phase 3 Not yet recruiting 144 enrolled Genrix (Shanghai) Biopharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.

Timeline

Start
2025-09-25
Primary completion
2027-05-15
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GR1802 Monoclonal antibody — —